Search
for
Sort by
Research 211–240 of 227
- Pathophysiology of Alopecia Areata in the Pediatric Patient
- From bedside to bench: regulation of host factors in SARS-CoV-2 infection
- AIRE Deficiency Leads to the Development of Alopecia Areata‒Like Lesions in Mice
- Phytochemicals for Hair Health Targeting Growth Signaling Molecules in Hair Follicular Stem Cells: A New Strategy for Hair Growth
- The Roles of Keratinocytes in the Initiation, Progression and Maintenance of Hidradenitis Suppurativa
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- Advances in the treatment of autosomal recessive congenital ichthyosis, a look towards the repositioning of drugs
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- The X Factor in Immunity: Sex Differences Shaped by the X Chromosome
- Update From Dermatology Nurses’ Association Convention 2025
- Integrated analysis of long non-coding RNA and mRNA expression in different colored skin of koi carp
- Discoid Lupus Erythematosus
- The Genetics of Seborrheic Dermatitis: A Candidate Gene Approach and Pilot Genome-Wide Association Study
- Association of Serum IL-17A and IL-23 Levels With Alopecia Areata: A Cross-Sectional Comparative Study
- Elevation of circulating DNAs of disease-associated cytokines in serum cell-free DNA from patients with alopecia areata
- Mendelian randomization study highlights hypothyroidism as a causal determinant of alopecia areata
- The Role of T‐Helper 17 Cells and Regulatory T Cells in Acute Diffuse and Total Alopecia: The Increased Function of Regulatory T Cells May Explain the Favorable Prognosis
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
- Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- A review of Janus kinase inhibitor use in scarring alopecia
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
- Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib
- Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
- Deucravacitinib in dermatology: current indication and existing off-label data
- Review of Promising Off-Label Use of Deucravacitinib
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)